Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A trial to assess efficacy in patients with advanced pretreated BRAFV600 wild-type melanoma
Excerpt:...Absence of a BRAF V600 mutation as determined by a validated test 5. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Excerpt:...BRAF mutation-positive and wild-type tumors are allowed....
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
Excerpt:...BRAF wild-type confirmed, and NRAS mutation assessed....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
Excerpt:...- Histologically or cytologically confirmed diagnosis of melanoma, pancreatic, colorectal cancer (CRC), non-small cell lung cancer, or other tumor with BRAF mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors
Excerpt:...Subject has documented evidence of a BRAF V600 mutation obtained from tumor tissue or liquid biopsy: (other protocol conditions may apply) 5....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
Excerpt:...- Absence of a BRAF V600 mutation as determined by a validated test....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Excerpt:...- BRAF mutation in loci other than V600 (BRAF nonV600 MUT) or BRAF fusion detected by genetic testing of the primary tumor or regional/distant metastasis...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma
Excerpt:...Able to provide evidence from an accredited laboratory of wt BRAF status for their melanoma, or ascertainment of wt BRAF status from a sample of melanoma provided for mutational analysis in Oxford (phase 2 part only). ...
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Excerpt:97 patients with melanoma were enrolled, including 81 with cutaneous or unknown primary melanoma (36 BRAF mutant, 39 BRAF wild-type, six BRAF status unknown), and 16 with uveal melanoma....Of 36 patients with BRAF mutations, 30 had not received a BRAF inhibitor before; two complete responses (both confirmed) and ten partial responses (eight confirmed) were noted in this subgroup (confirmed response rate, 33%).
DOI:10.1016/S1470-2045(12)70269-3